Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
According to data to be presented at the upcoming meeting of the American Society of Clinical Oncology (ASCO), enzalutamide monotherapy substantially reduces PSA levels in androgen deprivation therapy (ADT)-naive patients with progressive or high-risk disease (including men with evident metastases). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ADT, enzalutamide, first line, outcome, PSA | Leave a Comment »
The American Urological Association (AUA) sent the following additional message to its members with the past 90 minutes: … READ MORE …
Filed under: Diagnosis, Risk | Tagged: guideline, PSA, screening, testing | 8 Comments »
One of the things that is most interesting about the new guidelines issued by the AUA last week (see here for original announcement) is that they seem to be gaining reasonably widespread approval — probably because they are actually (and finally) based on actual evidence as opposed to raw opinion. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: guideline, PSA, risk, screening, testing | 14 Comments »
As of 7 am this morning, the American Urological Association (AUA) has issued a new set of guidelines on screening for prostate cancer. The full text of this set of guidelines is already available on the AUA web site. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: PSA, screening | 7 Comments »
A podium presentation by Kingman et al. at the upcoming annual meeting of the American Urological Association (AUA) may be among the most significant to be presented at the meeting. It seriously challenges the long-held belief about the need to routinely re-biopsy men initially diagnosed with high-grade prostatic intraepithelial neoplasia (HG-PIN). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, HG-PIN, high-grade, neoplasia, PSA, risk | Leave a Comment »
According to a recent analysis of data from the Finnish Prostate Cancer Screening Trial (which was the single largest contributor to the data collected in the European Randomized Study of Screening for Prostate Cancer or ERSPC), this Finnish trial showed no statistically significant reduction in mortality at 12 years of follow-up. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Finland, PSA, screening, testing, trial | 8 Comments »
The Clinical Guidelines Committee of the American College of Physicians (ACP) — one of the most influential primary care medical societies in the USA — has just issued a new set of guidelines on screening for prostate cancer. Many prostate cancer patients are likely to be deeply disturbed by these guidelines. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: ACP, American College of Physicians, guideline, PSA, screening | 7 Comments »
The March 2013 issue of the AUA News carries a strong message from two leading experts on the early diagnosis and treatment of localized prostate cancer regarding the appropriate use of PSA testing for risk of prostate cancer and consequent follow-up. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, PSA, screening, testing | 8 Comments »
We don’t want to suggest that the recent paper by a Japanese research team in the journal Andrology is necessarily going to revolutionize the diagnosis of clinically significant prostate cancer. A great deal more work would be required to justify the hypothesis that they put forward. On the other hand, their hypothesis is definitely interesting. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: androgen, chromatography, deprivation, dihydrotestosterone, mass spectrometry, PSA, risk, serum, testosterone, tissue | 9 Comments »
A new article on the Medscape Oncology web site (and again correlated with a media release sent out by the European Association for Urology [EAU] from their annual meeting in Milan, Italy) is headed “Prostate cancer vaccine shows promise.” However, the degree of that “promise” appears to be open to some question. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: castration, dexamethasone, multi-peptide, outcome, PSA, resistant, trial, vaccine | 7 Comments »
There were two posters presented at the Genitourinary Cancers Symposium regarding the use of “natural” agents in the management of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: acai, mushroom, PSA, recurrent | 7 Comments »
The print and online “Daily News” provided by the organizers of the Genitourinary Cancers Symposium here in Orlando offers additional articles today that may be of interest to many InfoLink readers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, C-11 choline, medicine, PET, precision, PSA, radiation, screening | Leave a Comment »
In the past few years Dr. Richard Ablin has published a number of articles and commentaries claiming that he “discovered” the PSA test. His claim has been controversial ever since he first made it, and a Letter to the Editor of The ASCO Post, published in the December 15, 2012, issue of the magazine, presented a very different point of view. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Albin, Catalona, Chu, discoverer, discovery, PSA, Stamey, test | Leave a Comment »
According to a media release issued last week by a relatively new company called True Diagnostics, Inc., they hope shortly to be able to introduce a new, “point of care” technical system that can be used to assay PSA levels from a “finger-prick” quantity of blood, thus allowing almost instant assessment of PSA levels in the doctor’s office. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: diagosis, monitoring, PSA, risk, testing | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site